SHANGHAI SERUM BIO-TECHNOLOGY released its semi-annual performance, with a net profit attributable to the parent company of 32.98 million yuan, a year-on-year increase of 2.07%

Zhitong
2025.08.25 09:09
portai
I'm PortAI, I can summarize articles.

According to the Zhitong Finance APP, SHANGHAI SERUM BIO-TECHNOLOGY disclosed its semi-annual report for 2025. During the reporting period, the company achieved revenue of 101 million yuan, a year-on-year increase of 2.82%; net profit attributable to shareholders was 32.98 million yuan, a year-on-year increase of 2.07%; net profit excluding non-recurring items was 28.53 million yuan, a year-on-year increase of 25.08%; basic earnings per share were 0.30 yuan. The company plans to distribute a cash dividend of 1.20 yuan (tax included) for every 10 shares to all shareholders

According to the Zhitong Finance APP, SHANGHAI SERUM BIO-TECHNOLOGY (688163.SH) disclosed its semi-annual report for 2025. During the reporting period, the company achieved revenue of 101 million yuan, a year-on-year increase of 2.82%; net profit attributable to shareholders was 32.98 million yuan, a year-on-year increase of 2.07%; net profit excluding non-recurring items was 28.53 million yuan, a year-on-year increase of 25.08%; basic earnings per share were 0.30 yuan. The company plans to distribute a cash dividend of 1.20 yuan (tax included) for every 10 shares to all shareholders

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.